Telix

Telix doses first patient in Phase 3 renal cancer trial

July 21, 2026 | 14:41

Telix Pharmaceuticals dosed the first patient in its Phase 3 LUTEON trial evaluating TLX250-Tx for relapsed or recurrent clear cell renal cell carcinoma, marking the first Phase 3 study of a CAIX-targeted radiopharmaceutical in this cancer type.

Telix reports Q2 revenue of US$247m

July 21, 2026 | 10:44

Telix Pharmaceuticals reported US$247 million in second-quarter revenue for the period ended 30 June 2026, providing a market update on commercial performance and pipeline progress across its radiopharmaceutical portfolio.

Telix completes Japan Phase 3 enrollment for Illuccix

July 17, 2026 | 10:23

Telix Pharmaceuticals, dual-listed on ASX and Nasdaq, completed patient enrollment in its pivotal Phase 3 registration study of TLX591-Px, branded Illuccix, for prostate cancer imaging in Japan.

Telix doses first patients in OPTIMAL-e prostate cancer trial

July 16, 2026 | 11:20

Telix Pharmaceuticals and St Vincent's Hospital announced the first patients have been dosed with TLX597-Tx in the OPTIMAL-e trial, targeting earlier stage prostate cancer treatment in Melbourne and Indianapolis.

Telix opens Australian-first radiopharmaceutical facility

July 16, 2026 | 11:13

Telix Pharmaceuticals, dual-listed on ASX and Nasdaq, officially opened a multi-million dollar radiopharmaceutical research, manufacturing and treatment facility in Melbourne, expanding Australia's sovereign cancer treatment manufacturing capacity.

Telix hosts webinar on theranostics for glioma and glioblastoma

June 23, 2026 | 16:41

Telix Pharmaceuticals has announced an educational webinar exploring unmet needs in neurologic oncology, focusing on glioma and glioblastoma and the potential role of theranostics.

Telix receives European acceptance for brain cancer imaging drug

May 02, 2026 | 10:18

The Australian radiopharmaceutical company's TLX101-Px diagnostic agent received marketing authorization application acceptance from European regulators.

Telix begins phase 3 trial for recurrent brain cancer treatment

April 15, 2026 | 09:42

The radiopharmaceutical company administered its TLX101-Tx therapy to the initial participant in late-stage testing for glioblastoma.

Telix prices and upsizes $600 million convertible bond offering

April 15, 2026 | 09:15

The Australian radiopharmaceutical company completed a larger-than-planned debt offering following strong investor demand for the equity-linked securities.

Telix and Regeneron form radiopharmaceutical partnership

April 13, 2026 | 09:43

The Australian nuclear medicine company and American biotech formed an alliance to develop targeted radiation therapies combining their technology platforms.

FDA accepts Telix brain cancer imaging drug application

April 10, 2026 | 10:42

The US regulator formally received the Australian company's new drug application for its TLX101-Px diagnostic imaging agent beginning review.

Telix appoints David Gill as non-executive director

April 02, 2026 | 09:45

The radiopharmaceutical company added Gill to its board in a supervisory governance role.

Telix resubmits brain cancer imaging drug application to FDA

March 16, 2026 | 10:02

The Australian radiopharmaceutical company filed an updated new drug application for its diagnostic imaging agent following previous regulatory feedback.